CYTOKINE RECEPTOR ZCYTOR17

• US 20070105777A1
• Filed: 01/08/2007
• Published: 05/10/2007
• Est. Priority Date: 06/26/2000
• Status: Abandoned Application

• Current Assignee: Zymogenetics Incorporated (Bristol-Myers Squibb Company)
• Original Assignee: Zymogenetics Incorporated (Bristol-Myers Squibb Company)
• Inventors: Gao, Zeren, Kuijper, Joseph, Whitmore, Theodore, Presnell, Scott, Sprecher, Cindy, Maurer, Mark
• Application Number:
  US11/620,994
• Publication Number:
  US 20070105777A1
• Time in Patent Office: Days
• US Class Current: 435/69.100
• CPC Class Codes: C07K 14/715 for cytokines; for lymphokines; for interferons

Abstract

Novel polypeptides, polynucleotides encoding the polypeptides, and related compositions and methods are disclosed for zcytor17, a novel cytokine receptor. The polypeptides may be used within methods for detecting ligands that stimulate the proliferation and/or development of hematopoietic, lymphoid and myeloid cells in vitro and in vivo. Ligand-binding receptor polypeptides can also be used to block ligand activity in vitro and in vivo. The polynucleotides encoding zcytorl7, are located on chromosome 5, and can be used to identify a region of the genome associated with human disease states. The present invention also includes methods for producing the protein, uses therefor and antibodies thereto.

Claims

1. An isolated polypeptide comprising an amino acid sequence having at least 95% sequence identity with amino acid residues 33-662 of SEQ ID NO:

54, wherein the polypeptide stimulates inflammation upon binding zcytor17 ligand.

2. The isolated polypeptide of claim 1 wherein the polypeptide comprises amino acid residues 1-662 of SEQ ID NO:

54.

3. The isolated polypeptide of claim 1 wherein the polypeptide consists of amino acid residues 33-662.

4. An isolated zcytor17 soluble receptor comprising an amino acid sequence having at least 95% sequence identity with amino acid residues 33-532 of SEQ ID NO:

54, wherein the zcytor17 soluble receptor reduces zcytor17 ligand induced inflammation.

5. The isolated zcytor17 soluble receptor of claim 4 wherein the zcytor17 soluble receptor is fused to a heavy chain constant region of an immunoglobulin.

6. The isolated zcytor17 soluble receptor of claim 5 wherein the heavy chain constant region of the immunoglobulin is human Fc4.

7. An isolated polypeptide comprising amino acid residues 33-662 of SEQ ID NO:

54.

8. The isolated polypeptide of claim 7 wherein the polypeptide comprises amino acid residues 1-662 of SEQ ID NO:

54.

9. An isolated zcytor17 soluble receptor comprising an amino acid sequence of 33-532 of SEQ ID NO:

54.

10. The isolated zcytor17 soluble receptor of claim 9 further comprising human immunoglobulin Fc4.

11. A composition comprising:

a polypeptide comprising amino acid residues 33-662 of SEQ ID NO;

54; and

a pharmaceutically acceptable vehicle.

12. A composition comprising:

a zcytor17 soluble receptor comprising amino acid residues 33-532 of SEQ ID NO;

54; and

a pharmaceutically acceptable vehicle.

13. The composition of claim 12 wherein the zcytor17 soluble receptor further comprises human immunoglobulin Fc4.